Medical News : India is set to witness the launch of a new blood lipid-lowering treatment this month that promises to drastically reduce levels of a ‘bad’ cholesterol or – low-density lipoprotein cholesterol (LDL-C) – in the blood, a primary risk factor for heart attacks and strokes. There is, however, a catch. At nearly Rs 1.2 lakh per jab, as revealed by the market sources, the drug – Inclisiran – may be unaffordable for a large number of the patients needing the therapy. Patients with high bad cholesterol would need two injections of the drug, produced by Swiss pharma giant Novartis, every year, said company sources.